185 related articles for article (PubMed ID: 22820730)
41. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.
Ke YY; Singh VK; Coumar MS; Hsu YC; Wang WC; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Shih C; Hsieh HP
Sci Rep; 2015 Jun; 5():11702. PubMed ID: 26118648
[TBL] [Abstract][Full Text] [Related]
42. Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.
Göring S; Bensinger D; Naumann EC; Schmidt B
ChemMedChem; 2015 Mar; 10(3):511-22. PubMed ID: 25677073
[TBL] [Abstract][Full Text] [Related]
43. A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.
Corsino P; Horenstein N; Ostrov D; Rowe T; Law M; Barrett A; Aslanidi G; Cress WD; Law B
J Biol Chem; 2009 Oct; 284(43):29945-55. PubMed ID: 19710018
[TBL] [Abstract][Full Text] [Related]
44. Conformational restriction of a type II FMS inhibitor leading to discovery of 5-methyl-
Im D; Moon H; Kim J; Oh Y; Jang M; Hah JM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1716-1721. PubMed ID: 31571509
[TBL] [Abstract][Full Text] [Related]
45. Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.
Li Z; Wang X; Eksterowicz J; Gribble MW; Alba GQ; Ayres M; Carlson TJ; Chen A; Chen X; Cho R; Connors RV; DeGraffenreid M; Deignan JT; Duquette J; Fan P; Fisher B; Fu J; Huard JN; Kaizerman J; Keegan KS; Li C; Li K; Li Y; Liang L; Liu W; Lively SE; Lo MC; Ma J; McMinn DL; Mihalic JT; Modi K; Ngo R; Pattabiraman K; Piper DE; Queva C; Ragains ML; Suchomel J; Thibault S; Walker N; Wang X; Wang Z; Wanska M; Wehn PM; Weidner MF; Zhang AJ; Zhao X; Kamb A; Wickramasinghe D; Dai K; McGee LR; Medina JC
J Med Chem; 2014 Apr; 57(8):3430-49. PubMed ID: 24641103
[TBL] [Abstract][Full Text] [Related]
46. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
[TBL] [Abstract][Full Text] [Related]
47. Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors.
Grimm SH; Gagestein B; Keijzer JF; Liu N; Wijdeven RH; Lenselink EB; Tuin AW; van den Nieuwendijk AMCH; van Westen GJP; van Boeckel CAA; Overkleeft HS; Neefjes J; van der Stelt M
Bioorg Med Chem; 2019 Mar; 27(5):692-699. PubMed ID: 30661740
[TBL] [Abstract][Full Text] [Related]
48. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
[TBL] [Abstract][Full Text] [Related]
49. Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics.
Zhao H; Caflisch A
Bioorg Med Chem Lett; 2013 Oct; 23(20):5721-6. PubMed ID: 23993776
[TBL] [Abstract][Full Text] [Related]
50. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
[TBL] [Abstract][Full Text] [Related]
51. Recent advances in FLT3 inhibitors for acute myeloid leukemia.
Tong L; Li X; Hu Y; Liu T
Future Med Chem; 2020 May; 12(10):961-981. PubMed ID: 32314599
[TBL] [Abstract][Full Text] [Related]
52. Development of a potent and selective FLT3 kinase inhibitor by systematic expansion of a non-selective fragment-screening hit.
Nakano H; Hasegawa T; Imamura R; Saito N; Kojima H; Okabe T; Nagano T
Bioorg Med Chem Lett; 2016 May; 26(9):2370-4. PubMed ID: 26995531
[TBL] [Abstract][Full Text] [Related]
53. 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Hsu JT; Yeh TK; Yen SC; Chen CT; Hsieh SY; Hsu T; Lu CT; Chen CH; Chou LH; Chiu CH; Chang YI; Tseng YJ; Yen KR; Chao YS; Lin WH; Jiaang WT
Bioorg Med Chem Lett; 2012 Jul; 22(14):4654-9. PubMed ID: 22726931
[TBL] [Abstract][Full Text] [Related]
54. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.
Hanan EJ; van Abbema A; Barrett K; Blair WS; Blaney J; Chang C; Eigenbrot C; Flynn S; Gibbons P; Hurley CA; Kenny JR; Kulagowski J; Lee L; Magnuson SR; Morris C; Murray J; Pastor RM; Rawson T; Siu M; Ultsch M; Zhou A; Sampath D; Lyssikatos JP
J Med Chem; 2012 Nov; 55(22):10090-107. PubMed ID: 23061660
[TBL] [Abstract][Full Text] [Related]
55. Cyclin-dependent kinase inhibitors.
Fischer PM; Endicott J; Meijer L
Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
[TBL] [Abstract][Full Text] [Related]
56. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.
Grandage VL; Everington T; Linch DC; Khwaja A
Br J Haematol; 2006 Nov; 135(3):303-16. PubMed ID: 16956345
[TBL] [Abstract][Full Text] [Related]
57. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
[TBL] [Abstract][Full Text] [Related]
58. Acid Mediated Ring Closing Metathesis: A Powerful Synthetic Tool Enabling the Synthesis of Clinical Stage Kinase Inhibitors.
William AD; Lee AC
Chimia (Aarau); 2015; 69(3):142-5. PubMed ID: 26507218
[TBL] [Abstract][Full Text] [Related]
59. Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1
Zhi Y; Wang Z; Yao C; Li B; Heng H; Cai J; Xiang L; Wang Y; Lu T; Lu S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731727
[TBL] [Abstract][Full Text] [Related]
60. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
